These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36276872)

  • 1. Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia.
    Wang W; Luo Q; Chen Q; Pang A; Fang K
    Evid Based Complement Alternat Med; 2022; 2022():8691835. PubMed ID: 36276872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia.
    Báez-Gutiérrez N; Rodríguez-Ramallo H; Moreno MA; Arboli ER; Abdel-Kader Martín L
    Ther Adv Hematol; 2021; 12():20406207211040335. PubMed ID: 34471510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience.
    Giudice V; Serio B; Ferrara I; Manzo P; Gorrese M; Pepe R; Bertolini A; D'Alto F; Verdesca F; Langella M; Filippelli A; Selleri C
    Front Pharmacol; 2022; 13():1052060. PubMed ID: 36618908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia.
    Hu RH; Su L; Lan XX; Chang XL; Hui WH; Guo YX; Zhao H; Zhang Y; Sun WL
    Anticancer Drugs; 2023 Mar; 34(3):344-350. PubMed ID: 36622759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia.
    Todisco E; Papayannidis C; Fracchiolla N; Petracci E; Zingaretti C; Vetro C; Martelli MP; Zappasodi P; Di Renzo N; Gallo S; Audisio E; Griguolo D; Cerchione C; Selleri C; Mattei D; Bernardi M; Fumagalli M; Rizzuto G; Facchini L; Basilico CM; Manfra I; Borlenghi E; Cairoli R; Salutari P; Gottardi M; Molteni A; Martini V; Lunghi M; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Cascavilla N; Rivellini F; Ferrara F; Maurillo L; Nanni J; Romano A; Cardinali V; Gigli F; Roncoroni E; Federico V; Marconi G; Volpi R; Sciumè M; Tarella C; Rossi G; Martinelli G;
    Cancer; 2023 Apr; 129(7):992-1004. PubMed ID: 36692409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America.
    Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D
    Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
    Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
    Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country.
    Mirgh S; Sharma A; Shaikh MRMA; Kadian K; Agrawal N; Khushoo V; Mehta P; Ahmed R; Bhurani D
    Am J Blood Res; 2021; 11(3):290-302. PubMed ID: 34322294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis.
    Du Y; Li C; Yan J
    Hematology; 2023 Dec; 28(1):2198098. PubMed ID: 37036307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9840736. PubMed ID: 37829626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
    Jasra S; Kazemi M; Shah N; Chen J; Fehn K; Wang Y; Mantzaris I; Kornblum N; Sica A; Bachier L; Goldfinger M; Gritsman K; Braunschweig I; Steidl U; Shastri A; Verma A
    Exp Hematol Oncol; 2021 Jan; 10(1):1. PubMed ID: 33397455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
    Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
    Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax-containing regimens in acute myeloid leukemia.
    Aldoss I; Pullarkat V; Stein AS
    Ther Adv Hematol; 2021; 12():2040620720986646. PubMed ID: 33628408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia].
    Wang Y; Huang SL; Zhang XX; Bian MR; Lin GQ; Si YJ; Zhang B; Wan Y; Wang L; Zhang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):327-332. PubMed ID: 37096501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
    Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment.
    Li Z; Wang J; Ge SS; Qiu QC; Du JH; Shan SS; Shen XD; Wan CL; Wang BR; Wu DP; Qiu HY; Xue SL
    Front Oncol; 2022; 12():841276. PubMed ID: 35211416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
    Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.